CAR T | pharmaphorum

Skip to main content

Monday 25 November 2024

twitter linkedin facebook rss

User account menu

Subscribe

Channels

Content type

Categories

Categories

Sort by

Order

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

close

Channels

Content type

Categories

Categories

Sort by

Order

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

Sign up

twitter linkedin facebook rss

Sign in

CAR T

News

kitepharma

Great news for Kite after CAR-T success in cancer patients

Kite looks all set for a regulatory approval later this year for its CAR-T drug KTE-CI9 after the company published encouraging topline primary results.

News

CellectisBest

Cellectis' ‘off the shelf’ CAR-T ready for trials

Trials of Cellectis’ UCART123 have been given the go-ahead by the FDA, which will make it the first ‘off the shelf’ CAR-T drug to enter trials in the US.

News

kitepharma

Kite aims for Asia market with CAR-T deals in China, Japan

California's Kite strikes deals with Fosun and Daiichi Sankyo.

News

Cancer-cell

Juno boosted by CAR-T trial findings in NHL

Biotech plans pivotal trial next year.

News

ariebelldegrunwhitesquare

Kite in CAR-T pole position as rolling submission begins

Kite to start filing data for KTE-C19 with US regulator.

News

Cancer attacked by T cells 600

Kite outlines vision for next gen cancer killing cells

Backed by Amgen, Kite outlines bold plan for developing CAR-T and TCR cells.

Load more results

Editor's Picks

Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn News

Neuralink gets okay for its first international trial

Trump picks celebrity doc Mehmet Oz to lead Medicare

Chasing $80bn sales target, AZ unveils $3.5bn US investment News

Syndax gets FDA okay for first-in-class leukaemia drug

News

BridgeBio poised to challenge Pfizer after Attruby approval

BridgeBio poised to challenge Pfizer after Attruby approval

BridgeBio grabs FDA approval for its ATTR cardiomyopathy drug Attruby, setting up a challenge to market leader Pfizer

Sales & Marketing

Happy lady reading from tablet

Coming soon: The Life Sciences Industry Report 2025 – insigh...

Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Subscribe

rss facebook linkedin twitter

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2024, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2024, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company